This article reviews the diagnostic criteria for both myalgic encephalomyelitis (ME) (ie, chronic fatigue syndrome) and fibromyalgia (FM) and describes how to differentiate them from depressive and anxiety disorders, the psychiatric conditions with which they are most often confused. The patients in the following Case Vignettes have ME and/or FM; not all have a psychiatric condition.
Despite thousands of peer-reviewed papers documenting their unique characteristics and pathophysiology, ME and FM continue to be mistaken for psychiatric conditions. This is problematic because it can delay accurate diagnosis and appropriate treatment, often for years. Although they have some symptoms in common (eg, fatigue, cognitive problems, unrefreshing sleep), ME and FM differ from each other and from all known psychiatric conditions. Diagnostic clarity depends on knowledge of the diagnostic criteria for each condition and identifying the pathognomonic, non-overlapping symptoms.
Diagnostic criteria for myalgic encephalomyelitis
The Canadian Consensus Criteria are used for diagnosis of ME. These criteria require the concurrent presence of disabling fatigue, postexertional malaise, unrefreshing sleep, muscle or joint pain, mood or cognitive symptoms, and at least 2 of the following: autonomic, neuroendocrine, or immune symptoms (Table 1).1 Postexertional malaise (immediate or delayed), the pathognomonic symptom of ME, is unusual in any psychiatric condition: most psychiatric patients feel better rather than worse after mental or physical exertion. Pain is not a core symptom of any common psychiatric condition but is reported to be elevated in major depression.2 Autonomic, neuroendocrine, and immune symptoms are not common in any psychiatric condition.
What new information does this article provide?
? Myalgic encephalomyelitis (ME) and fibromyalgia (FM) are complex biomedical conditions. Because psychiatric conditions are commonly comorbid, they should be looked for in patients with ME and FM.
What are the implications for psychiatric practice?
? Consider the diagnoses of ME and FM in “psychiatric” patients with a disproportionate number of physical symptoms, especially in those who are not responding as expected to psychiatric interventions.
Diagnostic criteria for fibromyalgia
New criteria for diagnosing FM were published in 2010.3 These criteria eliminate the previously required need for tender points on physical examination and add the criteria of fatigue, unrefreshing sleep, cognitive symptoms, and a long list of somatic symptoms (none of which are specific to FM) to the pathognomonic symptom of widespread pain (Table 2). Since fatigue, unrefreshing sleep, and cognitive symptoms are common to many psychiatric conditions, these new criteria do not aid in the differentiation between FM and a psychiatric diagnosis. A careful review of the entire constellation of symptoms is needed to identify whether the psychological or physical symptoms predominate. In patients with aching, tiring pain all over as the primary presenting symptom in combination with several other somatic symptoms, FM should be considered.
Maggie, aged 51, has suffered from chronic pain for several years since a skiing accident resulted in multiple surgeries on her broken ankle. In the past few years, this pain has become more generalized and is now associated with fatigue and cognitive problems. As she became increasingly unable to work, play, and socialize, depression developed. Now she feels “sick and tired” all the time with “pain all over” and lacks hope for the future.
Ben, aged 30, was a football star in college before coming down with Epstein Barr virus infection. He did not rest when he became ill because it was right before playoffs. He never fully recovered from this infection. He continues to feel “flu-like” most of the time and his energy “crashes” anytime he tries to do even modest amounts of exercise, such as playing with his young children. Since becoming ill, he has noticed a generalized worry about life. Even though his wife works and he has good family support, he cannot suppress the worry that “it will all fall apart.”
Joyce, aged 40, developed fatigue, “brain fog,” and “pain all over” after the difficult, premature birth of her second child. The child did not sleep through the night until he was 5 years old. When this child was 6 and starting school, Joyce thought she would finally be able to catch up on her sleep and rest. However, her health unaccountably took a turn for the worse and she experienced increased fatigue, orthostatic dizziness, difficulty in regulating temperature, and severe postexertional malaise. Her family physician diagnosed depression and prescribed an antidepressant. This, and other subsequent psychotropic trials, made her symptoms worse. She says she does not feel depressed, just really ill.
Prevalence of comorbidity
ME and FM can exist alone or together or can be comorbid with psychiatric conditions. The prevalence of Axis I conditions, particularly mood disorders, is higher in patients who have ME and FM than in healthy controls. The prevalence of psychiatric comorbidity is about the same in patients with ME as in patients with other chronic medical conditions; however, the rates are higher in patients who have FM. Estimates of comorbidity vary widely from study to study, which may be due to differences in sample types, variance in assessment tools for psychiatric diagnosis, and varying criteria being used for ME and FM. The variance is great enough that trying to estimate rates for individual comorbid psychiatric conditions is not helpful.
The prevalence of concurrent Axis I conditions among patients with ME ranges from 25% to 57%.4-6 The upper estimate comes from an epidemiological study that used flawed diagnostic criteria for ME.5,7 There is no evidence of any special relationship between ME and any psychiatric condition. In persons with ME, the prevalence of personality disorders is similar to that in the general population (less than10%) and much lower than that found in patients with depression.8,9
Rates of depression and anxiety are also variable in FM. The prevalence of “depressive disorders” ranges from 20% to 80% and of “anxiety disorders,” from 13% to 64%.10 Axis II diagnoses are identified in 8.7% of patients with FM.11 There is some overlap in the genetics and family clustering of FM, MDD, and dysthymia.12,13 In a recently published review on the connection between depression and FM, Gracely and colleagues14 conclude that while some categorize FM as an “affective spectrum disorder,” there are many alternative explanations for the high rates of depression and anxiety in patients with FM. Despite overlapping symptoms and family clustering, current opinion is that FM is not primarily an affective disorder.12,15
1. Carruthers BM, Jain AK, De Meirleir K, et al. Myalgic encephalomyelitis/chronic fatigue syndrome: clinical working case definition diagnostic and treatment protocols: a consensus document. J Chronic Fatigue Syndr. 2003;11:7-115.
2. Arnow BA, Hunkeler EM, Blasey CM, et al. Comorbid depression, chronic pain, and disability in primary care. Psychosom Med. 2006;68:262-268.
3. Wolfe F, Clauw DJ, Fitzcharles MA, et al. The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. Arthritis Care Res (Hoboken). 2010;62:600-610.
4. Fuller-Thomson E, Nimigon J. Factors associated with depression among individuals with chronic fatigue syndrome: findings from a nationally representative survey. Fam Pract. 2008;25:414-422.
5. Nater UM, Lin JM, Maloney EM, et al. Psychiatric comorbidity in persons with chronic fatigue syndrome identified from the Georgia population. Psychosom Med. 2009;71:557-565.
6. Hickie I, Lloyd A, Wakefield D, Parker G. The psychiatric status of patients with the chronic fatigue syndrome. Br J Psychiatry.1990;156:534-540.
7. Jason LA, Evans M, Brown A, et al. Sensitivity and specificity of the CDC empirical chronic fatigue syndrome case definition. Psychology.2010;1:9-16.
8. Courjaret J, Schotte CK, Wijnants H, et al. Chronic fatigue syndrome and DSM-IV personality disorders. J Psychosom Res.2009;66:13-20.
9. Nater UM, Jones JF, Lin JM, et al. Personality features and personality disorders in chronic fatigue syndrome: a population-based study. Psychother Psychosom.2010;79:312-318.
10. Fietta P, Fietta P, Manganelli P. Fibromyalgia and psychiatric disorders. Acta Biomed.2007;78:88-95.
11. Thieme K, Turk DC, Flor H. Comorbid depression and anxiety in fibromyalgia syndrome: relationship to somatic and psychosocial variables. Psychosom Med.2004;66:837-844.
12. Arnold LM, Hudson JI, Hess EV, et al. Family study of fibromyalgia. Arthritis Rheum.2004;50:944-952.
13. Raphael KG, Janal MN, Nayak S, et al. Psychiatric comorbidities in a community sample of women with fibromyalgia. Pain.2006;124:117-125.
14. Gracely RH, Ceko M, Bushnell MC. Fibromyalgia and depression. Pain Res Treat.2012;2012:486590. Epub 2011 Nov 19.
15. Pae CU, Luyten P, Marks DM, et al. The relationship between fibromyalgia and major depressive disorder: a comprehensive review. Curr Med Res Opin. 2008;24:2359-2371.
16. Stein E. Let Your Light Shine Through. http://eleanorsteinmd.ca. Accessed December 5, 2012.
17. White PD, Goldsmith KA, Johnson AL, et al; PACE Trial Management Group. Comparison of adaptive pacing therapy, cognitive behaviour therapy, graded exercise therapy, and specialist medical care for chronic fatigue syndrome (PACE): a randomised trial. Lancet. 2011;377:823-836.
18. Lorig KR, Sobel DS, Ritter PL, et al. Effect of a self-management program on patients with chronic disease. Eff Clin Pract. 2001;4:256-262.
19. Vercoulen JH, Swanink CM, Zitman FG, et al. Randomised, double-blind, placebo-controlled study of fluoxetine in chronic fatigue syndrome. Lancet. 1996;347:858-861.
20. Wearden AJ, Morriss RK, Mullis R, et al. Randomised, double-blind, placebo-controlled treatment trial of fluoxetine and graded exercise for chronic fatigue syndrome [published correction appears in Br J Psychiatry. 1998;173:89]. Br J Psychiatry. 1998;172:485-490.
21. Häuser W, Wolfe F, Tölle T, et al. The role of antidepressants in the management of fibromyalgia syndrome: a systematic review and meta-analysis. CNS Drugs. 2012;26:297-307.
22. Arnold LM, Rosen A, Pritchett YL, et al. A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder. Pain. 2005;119:5-15.
23. Nishishinya B, Urrútia G, Walitt B, et al. Amitriptyline in the treatment of fibromyalgia: a systematic review of its efficacy. Rheumatology (Oxford).2008;47:1741-1746.
24. Fisher MM, Rose M. Anaesthesia for patients with idiopathic environmental intolerance and chronic fatigue syndrome. Br J Anaesth. 2008;101:486-491.
25. Fitzcharles MA, Ste-Marie PA, Goldenberg D, et al. 2012 Canadian Guidelines for the Diagnosis and Management of Fibromyalgia Syndrome. Oshawa, Ontario: Canadian Pain Society; 2012:1-44.
26. Sublette ME, Ellis SP, Geant AL, Mann JJ. Meta-analysis of the effects of eicosapentaenoic acid (EPA) in clinical trials in depression. J Clin Psychiatry. 2011;72:1577-1584.
27. Jazayeri S, Tehrani-Doost M, Keshavarz SA, et al. Comparison of therapeutic effects of omega-3 fatty acid eicosapentaenoic acid and fluoxetine, separately and in combination, in major depressive disorder. Aust N Z J Psychiatry. 2008;42:192-198.
28. The International Fish Oil Standard Program. http://www.ifosprogram.com/industry-home. Accessed December 5, 2012.
29. Linde K, Berner MM, Kriston L. St John’s wort for major depression. Cochrane Database Syst Rev. 2008;(4):CD000448.
30. Rahimi R, Nikfar S, Abdollahi M. Efficacy and tolerability of Hypericum perforatum in major depressive disorder in comparison with selective serotonin reuptake inhibitors: a meta-analysis. Prog Neuropsychopharmacol Biol Psychiatry. 2009;33:118-127.
31. Arnold LM, Clauw DJ, Dunegan LJ, Turk DC; FibroCollaborative. A framework for fibromyalgia management for primary care providers. Mayo Clin Proc. 2012;87:488-496.